Tissue polypeptide specific antigen as a marker used to determine the liver diseases

Kathmandu University Medical Journal

Volumn 9, Issue 33, 2011, Pages 24-27

  Paul, D ^a   Biswas, R ^b   Habib, S H ^c  

^a Bangladesh Institute of Research and Rehabilitation in Diabetes Endocrine and Metabolic Disorders   (Bangladesh)

^b NORTH SOUTH UNIVERSITY   (Bangladesh)

^c Diabetic Association of Bangladesh   (Bangladesh)

Author keywords

Liver diseases; Marker; Tissue polypeptide specific antigen

Indexed keywords

ALPHA FETOPROTEIN; AMINOTRANSFERASE; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; TISSUE POLYPEPTIDE ANTIGEN;

ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CASE CONTROL STUDY; CHRONIC ACTIVE HEPATITIS; CONTROLLED STUDY; DIAGNOSTIC VALUE; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; RETROSPECTIVE STUDY;

EID: 84862248267     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v9i1.6257     Document Type: Article

References (17)

1. Rylander, Ziegler E, Bergman T. Molecular characterization of a tissue polypeptide specific antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem.1996;241:309-14.
2. Burt AD, Stewart JA, Aitchison M. Expression of tissue polypeptide antigen (TPA) in fetal and adult liver: changes in liver diseases. J Clin Pathol.1987; 40: 719-24.
3. Jalanko H, Kuusela PR, Sipponen, C Haglund and O Makela. Comparison of a new tumor marker, CA 19.9, with alpha-fetoprotein and carcinoembryonic antigen in-patients with upper gastrointestinal diseases. J. Clin. Pathol 1984;4: 218-222.
4. Oellerich, Burdelski M, Lautz B. Predictors of one year pretransplant survival in patients with cirrhosis. Hepatology 2001; 14: 1029-34.
5. Shabana A, Onsrud M. Tissue polypeptide specific antigen and CA 125 as serum tumor markers in ovarian carcinoma. Tumor Biol 1994; 15: 361-7.
6. Conejo JR, Benedito JE, Jimenez A. Diagnostic value of three tumor markers determined in pleural effusions. Eur J Clin Chem Clin Biochem 1996; 34: 139-42.
7. Leung N. Treatment of chronic hepatitis B: case selection and duration of therapy. J Gastroenterol Hepatol. 2002;17(4):409-14.
8. Glimelius B, Hoffmann K, Einarsson R. Monitoring palliative chemotherapy in advanced gastrointestinal cancer using serial tissue polypeptide specific antigen (TPS) measurements. Acta Oncol.1996;35:141-8.
9. Tramonti G, Ferdeghini M, Donadio C. Renal function and serum concentration of five tumor markers (TATI, SCC, CYFRA21-1,TPA, TPS) in patients without evidence of neoplasia. Cancer Detect Prev. 2000;24: 86-90.
10. Moraglio D, Pagano M, Galeazzi D, et al. Tissue polypeptide specific antigen (TPS) in liver disease. Clin Chim Acta. 1994;224:209-14.
11. Akbay A, Bozbaş A, Işgör Y. Serum dipeptidylpeptidase activity and tissue polypeptide specific antigen in patients with advanced cirrhosis: preliminary results. Clin Chim Acta. 2000;292:181-5.
12. Putzki H, Ledwoch J, Student A, et al. Tumor markers, carcinoembryonic antigen, tissue polypeptide antigen and carbonhydrate antigen 19.9 in liver diseases. J Surg Oncol. 1998;37:133-5.
13. Leandro G, Basso D, Fabris C, et al. Alpha-fetoprotein, tissue polypeptide antigen and ferritin in diagnosing primary hepatocellular carcinoma in patients with liver cirrhosis. J Cancer Res Clin Oncol.1989; 115:276-8.
14. Yeo W, Chan PKS, Zhang S, Ho WM, Steinberg JL, Tam JS et al. Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy. J Med Virol. 2000;62: 299-307.
15. Cetin T, Oǧuz A, Algan P, Yildirim IS.The use of tissue polypeptide specific antigen as a marker in liver diseases. Turk J Gastroenterol. 2003;14(3):177-80.
16. Stumptner C, Omary MB, Fickert P, Denk H, Zatloukal K. Hepatocyte cytokeratins are hyperphosphorylated at multiple sites in human alcoholic hepatitis and in a Mallory body mouse model. Am J Pathol. 2000;156:77-90.
17. Nakamura H, T. Katsumi S. Nagata, M. Saito, C. Konaka and H. Kato. A resected case of intralobal pulmonary sequestration with serum tumor markers, CA 19.9, CA125 and NCC-ST-439. Nippon Kyoba Shikkan Gakkai Zasshi.1997;35:1425-29.